Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW DRUGS

Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia

JHOP - December 2021 Vol 11, No 6 - FDA Oncology Update
Download PDF

On October 29, 2021, the FDA accelerated the approval of asciminib (Scemblix; Novartis AG), an oral kinase inhibitor, for the treatment of patients with chronic-phase Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) after receiving ≥2 tyrosine kinase inhibitors (TKIs), as well as for adults with chronic-phase Ph-positive CML that is associated with T315I mutation. The FDA granted asciminib breakthrough therapy and orphan drug designations for these indications.

The FDA approval of these 2 indications was based on results from 2 clinical trials. The first study was ASCEMBL, a multicenter, randomized, active-controlled, open-label clinical trial of 233 patients with chronic phase Ph-positive CML who previously received ≥2 TKIs. Patients were randomized in a 2:1 ratio and were stratified according to major cytogenetic response to asciminib 40 mg twice daily or to bosutinib (Bosulif) 500 mg once daily, until unacceptable adverse effects or treatment failure.

The main end point was major molecular response (MMR) at 24 weeks. The MMR rate was 25% (95% confidence interval [CI], 19-33) with asciminib versus 13% (95% CI, 6.5-23; P = .029) with bosutinib. At a median of 20-month follow-up, the median duration of MMR has not been reached.

The second study was CABL001X2101, a multicenter, open-label clinical trial that included 45 patients with chronic-phase Ph-positive CML and T315I mutation. All patients received asciminib 200 mg twice daily until unacceptable adverse events or treatment failure. The main end point was MMR. At 24 weeks, 42% (95% CI, 28%-58%) of the patients reached MMR. By 96 weeks, that rate was increased to 49% (95% CI, 34%-64%). The median duration of treatment was 108 weeks (range, 2-215 weeks).

The most common (≥20%) adverse events were upper respiratory tract infection, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. The most common laboratory abnormalities were decreased platelet counts, increased triglycerides, decreased neutrophil counts and hemoglobin, and increased creatine kinase, alanine aminotransferase, lipase, and amylase.

The recommended asciminib dose for patients with Ph-positive CML is 80 mg once daily, or 40 mg twice daily. The recommended dose for patients with T315I mutation is 200 mg twice daily.

Related Items
Cytalux, a Novel Imaging Agent, FDA Approved for Diagnosing Inoperable Ovarian Cancer Lesions
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination FDA Approved for Multiple Myeloma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda Now FDA Approved for Adjuvant Treatment of Renal-Cell Carcinoma
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecentriq First Immunotherapy FDA Approved for Adjuvant Treatment of Early-Stage Non–Small-Cell Lung Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Keytruda plus Chemotherapy FDA Approved for First-Line Treatment of Cervical Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
JHOP - December 2021 Vol 11, No 6 published on December 17, 2021 in FDA Oncology Update
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.